A dream of many pharmaceutical companies is to be able to register a large design space with the regulatory agencies. The problem is that this will require both time and money, so an intelligent method of validating a design space is needed. The design space should only cover operating points at which the process runs optimally. This means that the process should be optimized for different process scenarios and objective functions and the found operating points should be registered as design space. This paper presents a method of determining a good design space by creating Pareto fronts for the ideal case and for various process disturbance scenarios. Optimal operating points are found for varying ratios between feed costs and operating cos...
As defined by ICH [1] and FDA, Quality by Design (QbD) stands for “a systematic approach to developm...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...
This work presents a methodology for analyzing and optimizing preparative chromatographic processes....
As defined by ICH [1] and FDA, Quality by Design (QbD) stands for “a systematic approach to developm...
A new method for modelling chromatographic responses is presented as a critical piece for the achiev...
A new method for modelling chromatographic responses is presented as a critical piece for the achiev...
peer reviewedA new method for modelling chromatographic responses is presented as a critical piece f...
This paper presents a model-based method to aid in the process validation for the purification of ph...
One of the major issues in the pharmaceutical industry today is the cost of development and validati...
A framework is introduced for the systematic development of preparative chromatographic processes. I...
To design efficient and safe biopharmaceutical production processes, understanding the process and h...
AbstractA model based approach has been developed and used to identify robust operating conditions f...
There is a need to design and understand control strategies for biopharmaceutical processes. The con...
The Design Space (DS) of an analytical method is defined as the set of factor settings that provides...
As defined by ICH [1] and FDA, Quality by Design (QbD) stands for “a systematic approach to developm...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...
This work presents a methodology for analyzing and optimizing preparative chromatographic processes....
As defined by ICH [1] and FDA, Quality by Design (QbD) stands for “a systematic approach to developm...
A new method for modelling chromatographic responses is presented as a critical piece for the achiev...
A new method for modelling chromatographic responses is presented as a critical piece for the achiev...
peer reviewedA new method for modelling chromatographic responses is presented as a critical piece f...
This paper presents a model-based method to aid in the process validation for the purification of ph...
One of the major issues in the pharmaceutical industry today is the cost of development and validati...
A framework is introduced for the systematic development of preparative chromatographic processes. I...
To design efficient and safe biopharmaceutical production processes, understanding the process and h...
AbstractA model based approach has been developed and used to identify robust operating conditions f...
There is a need to design and understand control strategies for biopharmaceutical processes. The con...
The Design Space (DS) of an analytical method is defined as the set of factor settings that provides...
As defined by ICH [1] and FDA, Quality by Design (QbD) stands for “a systematic approach to developm...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...
Increasing molecular diversity and market competition requires biopharmaceutical manufacturers to in...